DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Negative impactCompany

AstraZeneca Pharma India Q1 results: Profit drops 32% to ₹37.93 crore

Business Standard 2 hrs ago·10 Aug 2026, 9:22 am

AstraZeneca Pharma India

This update concerns AstraZeneca Pharma India. Read the full report at the source below.

Affected stocks

Bearish1 stock

AstraZeneca Pharma India

ASTRAZEN Bearish

₹8,191.00

Bull / bear label is derived from the article's AI sentiment — indicative, not advice. Prices may be delayed.

Key takeaways

Concerns AstraZeneca Pharma India (ASTRAZEN).
Category: Company.
AI reads the tone as negative (potentially bearish) for the stock.

Why it matters

A routine update for AstraZeneca Pharma India. The tone is negative — watch for downside reaction. Use the price and stock snapshot to gauge how the market is responding.

Summary & analysis by DocStoX. Full story at Business Standard.